Daily Newsletter

15 November 2023

Daily Newsletter

15 November 2023

NHS sets sights on ending cervical cancer by 2040 with HPV vaccine drive

NHS chief executive Amanda Pritchard says vaccination and screening could make eliminating cervical cancer a reality in the next two decades.

Robert Barrie November 15 2023

The UK’s National Health Service (NHS) has pledged to eliminate cervical cancer by 2040, outlining how increasing rates of human papillomavirus (HPV) vaccination and screening will help it reach its goal.

The pledge was announced by NHS chief executive Amanda Pritchard at the NHS Providers’ annual conference held from 14 to 15 November.

The NHS said it will improve vaccine accessibility through targeted outreach and offering the jabs in more convenient settings such as libraries and community centres, according to a 15 November press release.

The NHS added that giving local health teams more flexibility in locating vaccine services, in addition to revamping the NHS App to improve access to online vaccine appointments, will help its aim to ensure as many people as possible are being vaccinated against HPV.

To reach cervical cancer elimination, there will need to be an incidence of lower than four per 100,000 women, as per the World Health Organization.

Currently, there are around 2,700 new cases of cervical cancer per year in England, based on the press release. According to Cancer Research UK, cervical cancer accounts for 2% of all new cancer cases in women.

In 99% of cases, cervical cancer is caused by the HPV virus, a common group of viruses transmitted through sexual and skin-to-skin contact. It is estimated around 80% of people will be infected with HPV at some point in their life.

The NHS originally introduced GSK’s bivalent HPV vaccine Cervarix to teenage girls in 2008, with research showing the vaccination programme has led to significant reductions in cervical cancer rates across multiple age groups.

Currently, the NHS offers MSD’s Gardasil 9 to both boys and girls aged 12 to 13 years and to those from higher-risk groups. Gardasil 9 protects against nine types of HPV. The Gardasil 9 regimen in England halved from two doses to one in September 2023.

Alongside the vaccination drive, the NHS also said it is inviting more patients for cervical screening. Last year, over five million people aged 25 to 64 years were invited for screening, with 3.5 million of those going through with the test.

Pritchard said: “Vaccination and screening are the key tools which mean we are one step closer to [eliminating cervical cancer] and the NHS is already making it easier than ever before for people to protect themselves and their families – whether it’s through community outreach in areas of lower uptake or expanding the NHS app so that everyone has their vaccine history and booking options in the palm of their hand.”

Cancer Research UK’s head of health and patient information Dr Julie Sharp said: “To ensure everyone has equal access to these life-saving programmes, there must be targeted action to increase HPV vaccination coverage and reduce barriers to cervical screening.

“This ambition will only be possible if the vaccination and screening programmes are backed by sufficient resources and modern IT infrastructure.”

Disease-modifying therapies (DMTs) entering the PD market pose significant opportunities and risks

As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs. However, the lack of validated predictive biomarkers of PD progression have made the development of DMTs and neuroprotective agents challenging.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.